Akero Therapeutics Inc
AKRO48.710USD
+0.340+0.70%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
3.88BCap. mercado
PérdidaP/E TTM
Más Datos de Akero Therapeutics Inc Compañía
Akero Therapeutics, Inc. is a clinical-stage company. The Company is developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH), a disease without any approved therapies. Efruxifermin (EFX), is its lead product candidate for MASH, which is being evaluated in the ongoing phase IIb SYMMETRY, phase III SYNCHRONY Histology, and phase III SYNCHRONY real-world studies. The phase III SYNCHRONY program builds on the results of two phase IIb clinical trials, the HARMONY study in patients with pre-cirrhotic MASH and the SYMMETRY study in patients with cirrhosis due to MASH. EFX is an analog of fibroblast growth factor 21 (FGF21), which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. EFX is designed to offer convenient once-weekly dosing.
Información de la empresa
Símbolo de cotizaciónAKRO
Nombre de la empresaAkero Therapeutics Inc
Fecha de salida a bolsaJun 20, 2019
Director ejecutivoDr. Andrew Cheng, M.D., Ph.D.
Número de empleados63
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 20
Dirección601 Gateway Boulevard, Suite 350
CiudadSOUTH SAN FRANCISCO
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal94080
Teléfono16504876488
Sitio Webhttps://akerotx.com/
Símbolo de cotizaciónAKRO
Fecha de salida a bolsaJun 20, 2019
Director ejecutivoDr. Andrew Cheng, M.D., Ph.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Andrew Cheng, M.D., Ph.D.
Dr. Andrew Cheng, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
306.19K
-8.92%
Dr. Jonathan Young, J.D., Ph.D.
Dr. Jonathan Young, J.D., Ph.D.
Chief Operating Officer, Executive Vice President, Secretary, Co-Founder
Chief Operating Officer, Executive Vice President, Secretary, Co-Founder
192.48K
-1.56%
Mr. Patrick Lamy
Mr. Patrick Lamy
Senior Vice President - Commercial Strategy
Senior Vice President - Commercial Strategy
32.93K
--
Ms. Catriona Yale
Ms. Catriona Yale
Chief Development Officer
Chief Development Officer
25.61K
--
Dr. Yuan Xu, Ph.D.
Dr. Yuan Xu, Ph.D.
Independent Director
Independent Director
9.40K
--
Mr. Mark T. Iwicki
Mr. Mark T. Iwicki
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Graham L. Walmsley, M.D., Ph.D.
Dr. Graham L. Walmsley, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Scott A. Gangloff
Mr. Scott A. Gangloff
Chief Technology Officer
Chief Technology Officer
--
--
Dr. Judy Chou, Ph.D.
Dr. Judy Chou, Ph.D.
Independent Director
Independent Director
--
--
Dr. Seth L. Harrison, M.D.
Dr. Seth L. Harrison, M.D.
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Andrew Cheng, M.D., Ph.D.
Dr. Andrew Cheng, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
306.19K
-8.92%
Dr. Jonathan Young, J.D., Ph.D.
Dr. Jonathan Young, J.D., Ph.D.
Chief Operating Officer, Executive Vice President, Secretary, Co-Founder
Chief Operating Officer, Executive Vice President, Secretary, Co-Founder
192.48K
-1.56%
Mr. Patrick Lamy
Mr. Patrick Lamy
Senior Vice President - Commercial Strategy
Senior Vice President - Commercial Strategy
32.93K
--
Ms. Catriona Yale
Ms. Catriona Yale
Chief Development Officer
Chief Development Officer
25.61K
--
Dr. Yuan Xu, Ph.D.
Dr. Yuan Xu, Ph.D.
Independent Director
Independent Director
9.40K
--
Mr. Mark T. Iwicki
Mr. Mark T. Iwicki
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 17 de may
Actualizado: sáb., 17 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
RTW Investments L.P.
9.31%
Janus Henderson Investors
8.87%
Wellington Management Company, LLP
7.45%
BlackRock Institutional Trust Company, N.A.
6.88%
General Atlantic LLC
6.57%
Other
60.94%
Accionistas
Accionistas
Proporción
RTW Investments L.P.
9.31%
Janus Henderson Investors
8.87%
Wellington Management Company, LLP
7.45%
BlackRock Institutional Trust Company, N.A.
6.88%
General Atlantic LLC
6.57%
Other
60.94%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor/Hedge Fund
45.11%
Investment Advisor
32.34%
Hedge Fund
15.98%
Private Equity
8.24%
Research Firm
3.82%
Venture Capital
2.68%
Individual Investor
1.28%
Foundation
0.41%
Pension Fund
0.28%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
489
88.09M
110.50%
+677.60K
2025Q1
495
89.01M
111.79%
+1.41M
2024Q4
453
76.50M
96.29%
-13.73M
2024Q3
445
77.37M
111.97%
-14.20M
2024Q2
428
76.12M
110.88%
-16.59M
2024Q1
421
77.80M
117.45%
+1.74M
2023Q4
401
63.49M
113.86%
-5.60M
2023Q3
387
61.40M
112.62%
-2.96M
2023Q2
363
60.44M
111.44%
+4.13M
2023Q1
350
52.43M
112.99%
-8.33M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
RTW Investments L.P.
7.42M
9.31%
+559.52K
+8.16%
Mar 31, 2025
Janus Henderson Investors
7.07M
8.87%
+1.03M
+17.14%
Mar 31, 2025
Wellington Management Company, LLP
5.94M
7.45%
-1.44M
-19.53%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
5.48M
6.88%
+346.72K
+6.75%
Mar 31, 2025
General Atlantic LLC
5.23M
6.57%
--
--
Mar 31, 2025
T. Rowe Price Associates, Inc.
4.73M
5.94%
+490.10K
+11.55%
Mar 31, 2025
The Vanguard Group, Inc.
4.22M
5.29%
+526.23K
+14.25%
Mar 31, 2025
Deep Track Capital LP
3.21M
4.03%
+1.72M
+115.45%
Mar 31, 2025
State Street Global Advisors (US)
2.49M
3.13%
+158.80K
+6.80%
Mar 31, 2025
UBS Financial Services, Inc.
2.16M
2.71%
+1.78M
+479.92%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
Simplify Propel Opportunities ETF
11.49%
Invesco Dorsey Wright Healthcare Momentum ETF
2.99%
ALPS Medical Breakthroughs ETF
2.87%
SPDR S&P Biotech ETF
1.26%
Tema Heart & Health ETF
1.03%
Virtus LifeSci Biotech Clinical Trials ETF
0.9%
Direxion Daily S&P Biotech Bull 3X Shares
0.72%
First Trust NASDAQ Pharmaceuticals ETF
0.6%
Invesco Nasdaq Biotechnology ETF
0.47%
ProShares Ultra Nasdaq Biotechnology
0.47%
Ver más
Simplify Propel Opportunities ETF
Proporción11.49%
Invesco Dorsey Wright Healthcare Momentum ETF
Proporción2.99%
ALPS Medical Breakthroughs ETF
Proporción2.87%
SPDR S&P Biotech ETF
Proporción1.26%
Tema Heart & Health ETF
Proporción1.03%
Virtus LifeSci Biotech Clinical Trials ETF
Proporción0.9%
Direxion Daily S&P Biotech Bull 3X Shares
Proporción0.72%
First Trust NASDAQ Pharmaceuticals ETF
Proporción0.6%
Invesco Nasdaq Biotechnology ETF
Proporción0.47%
ProShares Ultra Nasdaq Biotechnology
Proporción0.47%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
